undamentalytics Newsletter
Sign in

Alpha Teknova, Inc. (TKNO) stock

Add to watchlist

Add holding +

NASDAQ: TKNO Nasdaq Life Sciences Tools & Services Next results ~November 4, 2026

C+ Fundamentals grade

Alpha Teknova, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: free cash flow after stock pay is not positive.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Alpha Teknova, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders2 buying, 0 selling2 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds47 adding, 27 cuttingOf 12 active managers that changed their stake, 5 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Alpha Teknova files

Where Alpha Teknova stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $44m, up 12.3% on a year earlier, faster than the 9.3% growth a quarter earlier. Free-cash-flow margin rose to -16.8% from -27.0% a year earlier. Operating margin widened to -36.2% from -55.0%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 3 of our 6 financial-health checks.

Our model value for Alpha Teknova is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 4, 2026 (estimated)

Alpha Teknova, Inc.'s trailing-twelve-month revenue grew 12.3% year on year, with a free-cash-flow margin of -16.8%. Where it stands out: days sales outstanding of 45 days ranks 10 of 48 life sciences tools & services companies we cover. Where it lags: gross margin of 34.6% ranks 37 of 45 life sciences tools & services companies we cover.

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 32% in the quarter to 2026-06-30, the 4th beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Margins widening. Operating margin is up 18.8 points on a year ago.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Loss-making. Operating margin is -36.2%: costs exceed revenue.
  • Burning cash. Free cash flow was -16.8% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 81% and a beta of 1.3 against the S&P 500.
  • Below peers: gross margin. Gross margin of 34.6% ranks 37 of 45 life sciences tools & services companies we cover (median 52.0%).
  • Heavily shorted. 15.0% of the shares available to trade are sold short (5.4 days of average volume to cover).

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$0.05 against an average estimate of -$0.07: beat by 32.1%
Revenue
$12m, up 18.5% on a year earlier
Share reaction
-16.8% in the first session after the results on October 21, 2026, against -0.7% for the S&P 500
Next report
November 4, 2026

Alpha Teknova's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-4.8%
  • 1 week+6.4%
  • 1 month-22.0%
  • This year+84.5%
  • 1 year+33.5%
  • 5 years-69.5%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$43.7M
Operating margin
-36.2%
Net margin
-38.4%
EPS (TTM, diluted)
$-0.31

Growth

Revenue growth
+12.3%
Change in growth rate
+3.0 pts
Share count change
+1.0%

Cash

Free cash flow (TTM)
-$7.4M
FCF margin
-16.8%
Stock pay % of revenue
6.7%

Earnings

Last results
October 21, 2026
Next results (est.)
January 20, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Alpha Teknova, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Alpha Teknova, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 10.2%: the 10-year Treasury yield (4.9%) plus a beta of 1.18 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$0.7 ~$0.5–$0.9 Left out: out of range vs price (0.09x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$1.1 ~$1.3–$5.2 Left out: out of range vs price (0.15x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Alpha Teknova, Inc. with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$20.48$5.64$3.73$8.35$3.80$7.01
Market value$329m$158m$119m$390m$203m$376m
+ Net debt (− = net cash)−$76m−$20m−$15m$8m$7m$7m
Enterprise value$254m$138m$103m$399m$211m$383m
Multiples
Price / sales 8.9x3.8x3.2x10.3x5.0x8.6x
Price / earnings ——————
Price / free cash flow ——————
EV / EBITDA ——————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

13 /100

Weak moat

How hard Alpha Teknova's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -13.8% of total assets over 5 years.

  • Pricing power 5 / 20

    Gross margin has been a median 35.6%, moving by 10.9 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -52.4%; its worst year was -135.4%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -39.7% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (18 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 4, 2026, after the close. Analysts expect revenue of $12m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.29 +8% $46m +14%
Next −$0.19 — $53m +15%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −14.2% on 90 days ago. In the last 30 days, 5 analysts raised Alpha Teknova, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Alpha Teknova, Inc., last 90 days
−$0.40 −$0.30 −$0.20 −$0.10 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$0.34 Current fiscal year, 60 days ago: −$0.30 Current fiscal year, 30 days ago: −$0.30 Current fiscal year, 7 days ago: −$0.30 Current fiscal year, Now: −$0.29 −$0.29 Next fiscal year, 90 days ago: −$0.20 Next fiscal year, 60 days ago: −$0.20 Next fiscal year, 30 days ago: −$0.20 Next fiscal year, 7 days ago: −$0.20 Next fiscal year, Now: −$0.19 −$0.19

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$0.34−$0.20
60 days ago −$0.30−$0.20
30 days ago −$0.30−$0.20
7 days ago −$0.30−$0.20
Now −$0.29−$0.19

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.07 −$0.05 +32.1%
Mar 2026 −$0.09 −$0.08 +13.0%
Dec 2025 −$0.09 −$0.09 +2.2%
Sept 2025 −$0.09 −$0.08 +14.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

8 analysts, Oct 2026
Buy788%
Hold113%
Sell00%

Monthly trend

  1. Oct 2026718
  2. Sep 2026718
  3. Aug 2026617
  4. Jul 2026426

Counts of recommendations published by analysts covering Alpha Teknova, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
15.0%
of tradable shares
Days to cover
5.37
at average volume
Short interest, 1 month
+4%
to October 15, 2026
Held by institutions
76%
of shares
Held by insiders
8.1%
of shares
Employees
158
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Recent prices are available. Older price history and the statistics that need it are being loaded in the background.

What moved the share price

Last 12 months +33.5%

$5.25 on October 31, 2025 to $7.01

ThenNowEffect
Revenue (last 12 months) $39m $44m +12.3%
P/S multiple 7.2x 8.6x +20.1%
Share count 53m 54m −1.0%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 20222023202420252026 to date
Return
TKNO−73%−34%+124%−55%+85%
Industry peers (median)−51%−3%−15%−2%+15%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
TKNO42%50%42%25%64%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
TKNO−85%−73%−69%−61%−53%
S&P 500−25%−10%−8%−19%−9%

Worst fall since June 25, 2021: 96% from June 28, 2021 to July 5, 2024. Getting back needed a 2232% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.99 – $9.33
From 52-week high
−24.9%
vs 50-day average
−9.0%
vs 200-day average
+43.0%
Volatility (1 year)
81%
Beta vs S&P 500
1.31

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
8 up, 4 down
typical move ±8.7%
After a week
7 up, 5 down
typical move ±10.3%
After a month
6 up, 5 down
typical move ±31.0%
Results releasedNext dayS&P 500 next day5 days21 days
October 21, 2026 −16.8% −0.7% +6.4% —
August 5, 2026 +18.3% −0.4% +33.9% +31.2%
May 6, 2026 +7.0% +1.1% +4.5% +21.9%
February 26, 2026 +14.2% −1.0% −2.2% +19.9%
November 6, 2025 −4.8% −1.0% −10.5% −7.5%
August 7, 2025 −2.8% +0.7% +10.3% 0.0%
May 8, 2025 +16.2% +0.6% +8.7% −1.0%
March 4, 2025 +1.9% −0.1% −8.2% −6.8%
November 7, 2024 +3.9% +1.2% −4.8% +22.5%
August 13, 2024 −8.6% +2.0% +21.7% +12.3%
July 9, 2024 +1.2% +1.1% +12.0% +214.5%
May 13, 2024 +8.3% +0.5% −0.6% −3.3%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Alpha Teknova, Inc. in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Alpha Teknova, Inc.
$30M $35M $40M $45M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $36.7M Revenue (TTM), FY23 Q4: $36.7M Revenue (TTM), FY24 Q1: $36.9M Revenue (TTM), FY24 Q2: $34.9M Revenue (TTM), FY24 Q3: $36.3M Revenue (TTM), FY24 Q4: $37.7M Revenue (TTM), FY25 Q1: $38.3M Revenue (TTM), FY25 Q2: $38.9M Revenue (TTM), FY25 Q3: $39.8M Revenue (TTM), FY25 Q4: $40.5M Revenue (TTM), FY26 Q1: $41.8M Revenue (TTM), FY26 Q2: $43.7M $43.7M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $36.7M
FY23 Q4 $36.7M
FY24 Q1 $36.9M
FY24 Q2 $34.9M
FY24 Q3 $36.3M
FY24 Q4 $37.7M
FY25 Q1 $38.3M
FY25 Q2 $38.9M
FY25 Q3 $39.8M
FY25 Q4 $40.5M
FY26 Q1 $41.8M
FY26 Q2 $43.7M
Revenue growth, TTM YoY Alpha Teknova, Inc.
-20% -10% 0% 10% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -15.9% Revenue growth, TTM YoY, FY23 Q4: -11.4% Revenue growth, TTM YoY, FY24 Q1: -6.5% Revenue growth, TTM YoY, FY24 Q2: -10.9% Revenue growth, TTM YoY, FY24 Q3: -1.0% Revenue growth, TTM YoY, FY24 Q4: 2.9% Revenue growth, TTM YoY, FY25 Q1: 3.8% Revenue growth, TTM YoY, FY25 Q2: 11.4% Revenue growth, TTM YoY, FY25 Q3: 9.5% Revenue growth, TTM YoY, FY25 Q4: 7.4% Revenue growth, TTM YoY, FY26 Q1: 9.3% Revenue growth, TTM YoY, FY26 Q2: 12.3% 12.3%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -15.9%
FY23 Q4 -11.4%
FY24 Q1 -6.5%
FY24 Q2 -10.9%
FY24 Q3 -1.0%
FY24 Q4 2.9%
FY25 Q1 3.8%
FY25 Q2 11.4%
FY25 Q3 9.5%
FY25 Q4 7.4%
FY26 Q1 9.3%
FY26 Q2 12.3%
Operating margin (TTM) Alpha Teknova, Inc.
-150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -106.1% Operating margin (TTM), FY23 Q4: -96.9% Operating margin (TTM), FY24 Q1: -93.9% Operating margin (TTM), FY24 Q2: -93.6% Operating margin (TTM), FY24 Q3: -86.3% Operating margin (TTM), FY24 Q4: -69.3% Operating margin (TTM), FY25 Q1: -60.5% Operating margin (TTM), FY25 Q2: -55.0% Operating margin (TTM), FY25 Q3: -45.2% Operating margin (TTM), FY25 Q4: -41.9% Operating margin (TTM), FY26 Q1: -39.0% Operating margin (TTM), FY26 Q2: -36.2% -36.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -106.1%
FY23 Q4 -96.9%
FY24 Q1 -93.9%
FY24 Q2 -93.6%
FY24 Q3 -86.3%
FY24 Q4 -69.3%
FY25 Q1 -60.5%
FY25 Q2 -55.0%
FY25 Q3 -45.2%
FY25 Q4 -41.9%
FY26 Q1 -39.0%
FY26 Q2 -36.2%
FCF margin (TTM) Alpha Teknova, Inc.
-100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -98.9% FCF margin (TTM), FY23 Q4: -72.9% FCF margin (TTM), FY24 Q1: -58.1% FCF margin (TTM), FY24 Q2: -52.0% FCF margin (TTM), FY24 Q3: -41.9% FCF margin (TTM), FY24 Q4: -35.8% FCF margin (TTM), FY25 Q1: -29.2% FCF margin (TTM), FY25 Q2: -27.0% FCF margin (TTM), FY25 Q3: -26.3% FCF margin (TTM), FY25 Q4: -24.2% FCF margin (TTM), FY26 Q1: -21.7% FCF margin (TTM), FY26 Q2: -16.8% -16.8%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -98.9%
FY23 Q4 -72.9%
FY24 Q1 -58.1%
FY24 Q2 -52.0%
FY24 Q3 -41.9%
FY24 Q4 -35.8%
FY25 Q1 -29.2%
FY25 Q2 -27.0%
FY25 Q3 -26.3%
FY25 Q4 -24.2%
FY26 Q1 -21.7%
FY26 Q2 -16.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 31 37 41 37 38 41 44
Gross profit 18 18 17 10 7 13 15
EBITDA 7 −9 −46 −30 −20 −11 −10
Operating income 5 −12 −50 −36 −26 −17 −16
Net income 4 −10 −47 −37 −27 −17 −17
Diluted EPS $0.04 −$0.61 −$1.69 −$1.16 −$0.57 −$0.32 −$0.31
Growth (year on year)
Revenue — +17.9% +12.3% −11.4% +2.9% +7.4% +12.3%
EBITDA — −236.1% — — — — —
Operating income — −357.5% — — — — —
Net income — −374.6% — — — — —
Diluted EPS — <−999% — — — — —
Margins
Gross margin 56.7% 47.8% 42.2% 28.1% 19.2% 33.2% 34.6%
EBITDA margin 21.4% −24.7% −112.3% −81.5% −51.8% −26.2% −23.0%
Operating margin 14.9% −32.5% −119.9% −96.9% −69.3% −41.9% −36.2%
Net margin 11.4% −26.6% −114.6% −100.3% −70.9% −42.6% −38.4%
Free-cash-flow margin −9.5% −78.5% −134.1% −72.9% −35.8% −24.2% −16.8%
Cash flow
Cash from operations 3 −9 −27 −19 −12 −9 −6
Capital spending 5 20 28 8 1 1 1
Free cash flow −3 −29 −56 −27 −14 −10 −7
Stock-based pay 0 2 4 4 4 3 3
Free cash flow after stock pay −3 −30 −59 −31 −17 −13 −10
Balance sheet
Cash 3 88 42 28 4 6 6
Total debt 0 12 22 13 12 13 13
Net debt (negative = net cash) −3 −76 −20 −15 8 7 7
Diluted shares 15m 16m 28m 32m 47m 53m 54m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

3 of 6 checks passed · June 30, 2026
What it owns · $96m
Short-term assets $31mLonger-term assets $65m
What it owes, and who funded it · $96m
Short-term liabilities $7mLonger-term liabilities $26mShareholders' equity $63m
  • Short-term assets cover short-term liabilities $31m of assets due within a year against $7m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $31m short-term assets against $26m of longer-dated liabilities.
  • More cash than debt $6m of cash against $13m of debt.
  • Debt below 40% of shareholders' equity Debt is 21% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 8% to 21% over five years.
  • A year's operating cash flow covers at least 20% of debt −$6m of operating cash flow against $13m of debt.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Alpha Teknova, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+1.0%
year over year
R&D spending
5.1%
of revenue
Days sales outstanding
45 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated TKNO OABI RPID CSBR PRPO MASS Median
Revenue, last 12 months $44m $40m $35m $61m $61m $61m $229m
Revenue growth, last 12 months 12.3% 90.6% 16.1% 6.7% 29.5% 13.4% 6.9%
Revenue growth, 3-year average 3.7% −14.7% 22.5% 4.8% 43.6% 7.5% 2.9%
Revenue growth, latest quarter 18.5% 78.3% 10.9% 8.8% 21.9% 23.3% 8.5%
Gross margin 34.6% — — 49.8% 19.7% 52.2% 51.9%
Operating margin −36.2% −115.9% −141.5% −1.7% −2.5% −64.0% −14.3%
Operating margin, 3-year average −61.6% −278.2% −171.1% −1.2% −12.0% −87.7% −22.4%
Net margin −38.4% −108.1% −145.6% −1.8% −2.0% −57.0% −16.1%
Cash from operations / revenue −14.4% 6.6% −113.9% −9.2% 1.8% 2.5% 1.3%
Free-cash-flow margin −16.8% 5.9% −114.8% −10.1% 1.3% 1.0% −2.2%
Free-cash-flow margin, 3-year average −32.0% −130.3% −143.5% −0.4% −12.5% −38.7% 0.6%
Stock pay / revenue 6.7% 32.7% 12.3% 3.0% 3.4% 16.2% 4.4%
Change in share count 1.0% 19.2% 4.4% −2.4% 13.3% 4.3% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth 12.3% 6.9% 18 of 54
Change in growth rate Growth +3.0pp +0.4pp 14 of 54
Gross margin Profitability 34.6% 52.0% 37 of 45
Operating margin Profitability -36.2% -14.3% 34 of 52
Net margin Profitability -38.4% -12.2% 37 of 54
Free-cash-flow margin Cash generation -16.8% -1.3% 36 of 54
Stock pay as % of revenue Cash generation 6.7% 4.4% 31 of 53
Long-term debt as % of assets Balance sheet 13.8% 26.3% 10 of 35
Change in share count Balance sheet 1.0% 1.0% 23 of 46
Days sales outstanding Balance sheet 45 days 62 days 10 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Lab Essentials $31M 76.6% ▲ 7.5%
Clinical Solutions $7.7M 18.9% ▲ 7.8%
Other Product $1.8M 4.5% ▲ 3.5%
Geography
Region Revenue Share YoY
United States $38.2M 94.4% ▲ 6.5%
Outside the US $2.3M 5.6% ▲ 24.4%

From Alpha Teknova, Inc.'s 10-K filed March 2, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$51.7M
Institutions reporting
80
Shares held vs prior quarter
▲ 19.3%
Positions opened / closed
12 / 8

Top buyers and sellers, Q2 2026: 47 institutions bought and 27 sold ; the biggest buyer was Vanguard Capital Management LLC (+1.2M shares) and the biggest seller Millennium Management LLC (−372K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Royce & Associates LP $9.4M 1.7M 18.2% ▲ 55.4%
Vanguard Capital Management LLC $9.2M 1.6M 17.7% ▲ 265.3%
Roubaix Capital, LLC $9M 1.6M 17.3% ▼ 16.1%
Blackrock, Inc. $5M 880K 9.7% ▲ 22.7%
UBS Group AG $3.6M 632K 6.9% ▲ 94.4%
Conestoga Capital Advisors, LLC $1.8M 315K 3.5% ▼ 0.8%
Geode Capital Management, LLC $1.8M 312K 3.4% ▲ 1.3%
Bank Of America Corp $1.5M 256K 2.8% ▲ 12.0%
Goldman Sachs Group Inc $977,057 172K 1.9% ▲ 45.2%
State Street Corp $936,547 165K 1.8% ▲ 6.3%
AQR Capital Management LLC $646,236 114K 1.2% ▲ 71.3%
Bank Of New York Mellon Corp $604,465 106K 1.2% ▲ 6.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Alpha Teknova, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $143,500 2 trades by 2 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $143,500 net buying
Insider Date Trade Shares Price Value
Gunstream Stephen President and CEO March 6, 2026 Buy 26,000 $2.15 $55,900
Lowell Matthew Chief Financial Officer March 6, 2026 Buy 40,000 $2.19 $87,600

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 20, 2027 estimated from the company's past filing pattern, not announced

  • October 21, 2026
  • August 5, 2026
  • May 6, 2026
  • February 26, 2026
  • November 6, 2025
  • August 7, 2025

Recent SEC filings

Data status

When each part of this page on Alpha Teknova, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Alpha Teknova, Inc. in brief

What does Alpha Teknova, Inc. do?
Alpha Teknova, Inc. is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Alpha Teknova, Inc.'s stock ticker?
Alpha Teknova, Inc. trades under the ticker TKNO on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Alpha Teknova, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Alpha Teknova, Inc. reported revenue of $43.7M, 12.3% higher than a year earlier, according to its SEC filings.
What is Alpha Teknova, Inc.'s free cash flow?
Alpha Teknova, Inc.'s free-cash-flow margin is -16.8% of revenue over the trailing twelve months, ranking 36 of the 54 life sciences tools & services companies we cover.
Who are Alpha Teknova, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Royce & Associates LP, Vanguard Capital Management LLC and Roubaix Capital, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Alpha Teknova, Inc.'s market cap?
On November 2, 2026, Alpha Teknova, Inc.'s market capitalisation was about $376M and net debt of $7.2M. Market figures come from third-party market data and may be delayed.
How much debt does Alpha Teknova, Inc. have?
Alpha Teknova, Inc.'s debt-to-equity ratio is 21.1%, from its latest balance sheet (8.3% five years earlier). The financial health section below sets out its other solvency checks.
Who are Alpha Teknova, Inc.'s competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Alpha Teknova, Inc. are Omniab, Inc., Rapid Micro Biosystems, Inc., Champions Oncology, Inc., Precipio, Inc. and 908 Devices Inc. The side-by-side comparison below sets their revenue, margins and growth against Alpha Teknova, Inc.'s.
Are insiders buying or selling Alpha Teknova, Inc. stock?
Over the last 12 months, Alpha Teknova, Inc.'s directors and officers reported 2 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Alpha Teknova, Inc.'s next earnings date?
Around November 4, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Alpha Teknova, Inc. announces its own schedule.